Table 3. Grade 3 or 4 AEs during the combination of gefitinib and radiotherapy (weeks 1 to 11).
| Toxicity | Number of patients N (%) | AEs N | Related to gefitinib-RT Number of patients |
|---|---|---|---|
| Gastrointestinal disorders | 2 (12.5%) | 2 | 2 |
| Esophagitis | 2 (12.5%) | 2 | 2 |
| General disorders | 2 (12.5%) | 2 | 2 |
| Fatigue | 2 (12.5%) | 2 | 2 |
| General physical deterioration | 1 (6.3%) | 1 | 1 |
| Investigations | 2 (12.5%) | 2 | 1 |
| ALT increased | 1 (6.3%) | 1 | 1 |
| AST increased | 1 (6.3%) | 1 | 1 |
| Hemoglobin decreased | 1 (6.3%) | 1 | 0 |
| Respiratory disorders | 2 (12.5%) | 2 | 0 |
| Cough | 1 (6.3%) | 1 | 0 |
| Dyspnea exacerbated | 1 (6.3%) | 1 | 0 |
| Pneumonia | 1 (6.3%) | 1 | 0 |
| Cardiac disorders | 1 (6.3%) | 1 | 1 |
| Atrioventricular block | 1 (6.3%) | 1 | 1 |
| Procedural complications | 1 (6.3%) | 1 | 1 |
| Interstitial pneumonitis* | 1 (6.3%) | 1 | 1 |
| Metabolism and nutrition disorders | 1 (6.3%) | 1 | 0 |
| Dehydration | 1 (6.3%) | 1 | 0 |
| Vascular disorders | 1 (6.3%) | 1 | 0 |
| Deep vein thrombosis | 1 (6.3%) | 1 | 0 |
AEs: adverse events, N: number of, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, RT: radiotherapy.
*Grade 5